R. Schwerdtfeger

发表

Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

M. Labopin, A. Bosi, F. Frassoni, 2004, The New England journal of medicine.

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

W. Siegert, G. Ledderose, H. Gschaidmeier, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

M. Labopin, J. Finke, M. Mohty, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

R. Porcher, G. Mufti, C. Craddock, 2017, Bone Marrow Transplantation.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

N. Kröger, J. Finke, A. Nagler, 2016, Annals of Hematology.

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).

H. Deeg, N. Kröger, M. Sorror, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study

C. Meisner, G. Behre, L. Kanz, 2012, Haematologica.

Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy

C. Haferlach, H. Kolb, R. Schwerdtfeger, 2007, Leukemia & lymphoma.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation

N. Kröger, D. Atanackovic, A. Zander, 2008, Haematologica.

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

P. Dreger, H. Serve, A. Kiani, 2013, Leukemia.

Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation

P. Schirmacher, H. Baba, F. Wrba, 2014, Virchows Archiv.

Impact of HSCT Conditioning and Glucocorticoid Dose on Exercise Adherence and Response

M. Bohus, P. Dreger, J. Wiskemann, 2017, Medicine and science in sports and exercise.

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

W. Siegert, A. Zander, G. Ehninger, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.

N. Kröger, A. Zander, B. Fehse, 2002, Blood.

Prospective clinical evaluation of a LightCyclerTM‐mediated polymerase chain reaction assay, a nested‐PCR assay and a galactomannan enzyme‐linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients

R. Hehlmann, T. Südhoff, S. Reuter, 2004, British journal of haematology.

Modelling of LDL-apheresis: System efficacy and rebound kinetics

I. Schwaner, R. Schwerdtfeger, W. Schwartzkopff, 1988 .

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

N. Kröger, A. Nagler, A. Zander, 2004, Leukemia.

Prospective clinical evaluation of a LightCycler TM -mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer

S. Reuter, Innere Medizin, D. Buchheidt, 2004 .

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

A. Ganser, G. Mufti, N. Kröger, 2015, British journal of haematology.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

H. Einsele, N. Kröger, A. Zander, 2009, Blood.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

W. Hiddemann, N. Kröger, P. Dreger, 2012, The Lancet. Oncology.

Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis.

W. Siegert, H. Gollnick, C. Orfanos, 1994, Bone marrow transplantation.

Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease

G. Ledderose, S. Schnittger, C. Schoch, 2004, Bone Marrow Transplantation.

Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis

N. Kröger, A. Zander, E. Holler, 2012, British journal of haematology.

HLA-E polymorphisms in hematopoietic stem cell transplantation.

D. Fürst, H. Schrezenmeier, R. Arnold, 2011, Tissue antigens.

CD14+ peripheral blood mononuclear cells from chronic myeloid leukemia and normal donors are inhibitory to short- and long-term cultured colony-forming cells.

R. Hehlmann, B. Heissig, S. Rossol, 2000, Leukemia research.

Aspergillus specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis

T. Boch, W. Hofmann, P. M. Deckert, 2019, Mycoses.

Aspergillus PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities

C. Heussel, W. Hofmann, H. Wolf, 2013, Journal of Clinical Microbiology.

Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies.

W. Hofmann, S. Reuter, S. Krause, 2012, The Journal of antimicrobial chemotherapy.

The cholesterol theory of myocardial infarct

W. Hopfenmüller, R. Schwerdtfeger, H. Baeyer, 1992 .

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.

K. Schwarz, H. Einsele, M. Pfreundschuh, 2013, Blood.

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

W. Hiddemann, K. Spiekermann, E. Holler, 2011, Haematologica.

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia

C. Craddock, A. Zander, M. Labopin, 2011, Leukemia.

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

M. Labopin, C. Huber, A. Yaman, 2005, Bone Marrow Transplantation.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia

N. Kröger, A. Zander, G. Ehninger, 2003, Annals of Hematology.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

M. Mohty, E. Holler, H. Greinix, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

H. Einsele, M. Egger, C. Schmoor, 2009, The Lancet. Oncology.

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

W. Hiddemann, G. Ledderose, M. Hallek, 2006, Blood.

Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the

J. Esteve, R. Foà, M. Labopin, 2021, Leukemia.

Treatment of Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma Using Prednisone with or without the COPBLAM/IMVP-16 Regimen

M. Engelhard, G. Brittinger, D. Huhn, 1992, Annals of Internal Medicine.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

Dose‐reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis

W. Siegert, N. Kröger, V. Runde, 2001, British journal of haematology.

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

A. Ganser, N. Kröger, C. Craddock, 2016, Journal of Hematology & Oncology.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV

Martin C. Müller, J. Hasford, A. Zander, 2008 .

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.

N. Kröger, A. Zander, J. Thiele, 2007, Experimental hematology.

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

T. Lipp, C. Schoch, H. Gschaidmeier, 2004, Blood.

Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells

N. Schmitz, W. Siegert, H. Einsele, 2001, Annals of Hematology.

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor

W. Siegert, G. Ehninger, K. Höffken, 2003, Bone Marrow Transplantation.

Antidotal Effects of Non-Specific Reversal Agents On Anticoagulant-Induced Inhibition of Thrombin Generation.

M. Krause, T. Scholz, R. Schwerdtfeger, 2012 .

Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation

H. Einsele, A. Elmaagacli, D. Bunjes, 2003, Transplantation.

Safety and Efficacy of Itraconazole Compared to Amphotericin B as Empirical Antifungal Therapy for Neutropenic Fever in Patients with Haematological Malignancy*

A. Glasmacher, G. Ehninger, W. Aulitzky, 2007, Oncology Research and Treatment.

Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT

A. Ganser, L. Kanz, M. Labopin, 2017, British journal of haematology.

Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens.

V. Rickerts, E. Presterl, V. Jacobi, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

R. Porcher, G. Mufti, C. Craddock, 2017, Bone Marrow Transplantation.

(Ph+ ALL) outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2013 .

ALL) + (Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2009 .

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

N. Kröger, A. Zander, R. Brand, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS)

H. Deeg, M. Sorror, P. Valent, 2009 .

Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT

J. Esteve, A. Ganser, F. Baron, 2016, Haematologica.

N. Kröger, A. Zander, R. Brand, 2009 .

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.

H. Einsele, N. Kröger, A. Zander, 2004, Blood.

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

R. Naumann, G. Ehninger, C. Thiede, 1999, Transplantation.

A prospective, randomised study on the use of well-ﬁtting masks for prevention of invasive aspergillosis in high-risk patients

W. Ludwig, D. Buchheidt, G. Maschmeyer, 2009 .

Diagnostic Performance of an Aspergillus-Specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis

W. Hofmann, S. Reuter, D. Buchheidt, 2013, PloS one.

Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue

A. Neubauer, C. Thiede, M. Ritter, 2005, Annals of Hematology.

Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation

H. Kolb, B. Hertenstein, C. Koenecke, 2016, Bone Marrow Transplantation.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. Miguel, C. Bokemeyer, N. Kröger, 2008, Leukemia.

Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients

C. Lanvers-Kaminsky, G. Hempel, G. Würthwein, 2011, Antimicrobial Agents and Chemotherapy.

Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients

J. Gerss, C. Lanvers-Kaminsky, A. Groll, 2010, Antimicrobial Agents and Chemotherapy.

Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

A. Ho, C. Junghanss, G. Ehninger, 2012, The Lancet.

A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients.

W. Ludwig, D. Buchheidt, G. Maschmeyer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Invasive Trichosporon cutaneum (beigelii) infection in a patient with relapsed acute myeloid leukemia undergoing bone marrow transplantation.

D. Huhn, W. Siegert, G. Henze, 1988, Transplantation.

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.

A. Ganser, N. Kröger, M. Labopin, 2013, Blood.

Foscarnet – an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?

R. Naumann, G. Ehninger, M. Bornhäuser, 2000, Annals of Hematology.

Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants.

H. Doerr, J. Garson, W. Preiser, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

A. Ganser, G. Mufti, N. Kröger, 2021, British journal of haematology.

Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study.

M. Levitt, R. Greinwald, S. Elad, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

N. Kröger, G. Ehninger, H. Wandt, 2006, European journal of haematology.

Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005 .

N. Kröger, A. Zander, R. Brand, 2010, British journal of haematology.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. San Miguel, J. Miguel, C. Bokemeyer, 2008, Leukemia.

Cascade plasmapheresis with online membrane regeneration: Laboratory and clinical studies☆

R. Schwerdtfeger, H. Baeyer, F. Kochinke, 1985 .

ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)

N. Kröger, G. Ehninger, M. Bornhäuser, 2003, Bone Marrow Transplantation.

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

A. Ho, U. Hegenbart, G. Ehninger, 2002, Leukemia.

Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia

H. Fülle, H. Rühl, R. Schwerdtfeger, 1981, Klinische Wochenschrift.

Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

H. Einsele, A. Zander, A. Nagler, 2007 .

Fractionated total body irradiation and high-dose VP-16 with purged autologous bone marrow rescue for children with high risk relapsed acute lymphoblastic leukemia.

W. Siegert, G. Henze, S. Serke, 1993, Bone marrow transplantation.

Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.

B. Hertenstein, C. Koenecke, H. Kolb, 2008 .

Autologous and Allogeneic Bone Marrow Transplantation After Identical High-Dose Chemo-Radiotherapy in Children with Relapsed ALL

W. Siegert, G. Henze, I. Schmidt-Wolf, 1994 .

High-Dose VP-16 (HD VP-16) and Fractionated Total Body Irradiation (F-TBI) Followed by Autologous Bone Marrow Transplantation (ABMT) in Children with Relapsed or High-Risk Acute Lymphoblastic Leukemia (ALL)

W. Siegert, H. Schmid, R. Dopfer, 1992 .

A Therapeutic Platelet Transfusion Strategy without Routine Prophylactic Transfusion Is Feasible and Safe and Reduces Platelet Transfusion Numbers Significantly: Preliminary Analysis of a Randomized Study in Patients after High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantat

G. Ehninger, M. Schaich, M. Schubert, 2008 .

Efficacy of exercise training in SCT patients-who benefits most?

C. Ulrich, M. Bohus, P. Dreger, 2014, Bone Marrow Transplantation.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

J. Esteve, A. Ganser, N. Kröger, 2017, Journal of Hematology & Oncology.

Graft-versus-host disease or graft-versus-host-like syndrome [letter; comment]

W. Siegert, J. Beyer, R. Schwerdtfeger, 1992 .

Graft-versus-host disease or graft-versus-host-like syndrome.

W. Siegert, J. Beyer, R. Schwerdtfeger, 1992, Blood.

Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution.

G. Behre, L. Kanz, R. Handgretinger, 2009 .

Christoph Schmid, Hans Martin, Bernd Hertenstein, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

H. Einsele, M. Egger, C. Schmoor, 2011, Blood.

Allogeneic Transplantation of Purified Peripheral Blood Stem Cells from Unrelated Donors

G. Ehninger, M. Bornhäuser, U. Schuler, 1998 .

N. Schmitz, N. Kröger, A. Zander, 2002, Blood.

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

N. Kröger, O. Kuss, D. Niederwieser, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis

W. Siegert, N. Kröger, A. Zander, 2004, Bone Marrow Transplantation.

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

V. Diehl, A. Ganser, A. Zander, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation.

C. Ulrich, M. Bohus, P. Dreger, 2011, Blood.

Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors.

G. Ehninger, M. Bornhäuser, K. Frank, 2004, Blood.

Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)

D. Aust, J. Hampe, G. Baretton, 2014, BMC Gastroenterology.

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.

N. Schmitz, A. Ganser, R. Brand, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. Ganser, N. Kröger, M. Labopin, 2016, Journal of Hematology & Oncology.

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.

W. Hiddemann, E. Holler, P. Tschanter, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.

H. Einsele, C. Schmoor, A. Zander, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.

U. Hegenbart, G. Ehninger, B. Schlegelberger, 2012, Blood.

Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.

G. Bug, R. Schwerdtfeger, H. Baurmann, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT

J. Esteve, N. Kröger, C. Craddock, 2016, Haematologica.

Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.

N. Schmitz, A. Ganser, R. Brand, 2007 .

Mechanism of Donor to Host Tolerance in Rat Bone Marrow Chimeras

G. Santos, R. Schwerdtfeger, P. Tutschka, 1977 .

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

N. Kröger, S. Iacobelli, A. Zander, 2005, British journal of haematology.

Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.

H. Einsele, A. Hinke, O. Sezer, 2011, Blood.

Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study

T. Stübig, R. Schwerdtfeger, M. Schleuning, 2009, Bone Marrow Transplantation.

Petreatment with Rituximab Reduces the Incidence of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation in Patients with B Cell Lymphoma.

G. Ehninger, M. Hänel, F. Kroschinsky, 2004 .

Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes.

W. Siegert, H. Oettle, C. Schmidt, 1994, Bone marrow transplantation.

Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation.

H. Doerr, W. Preiser, F. B. Kraus, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).

A. Ganser, E. Holler, H. Greinix, 2008 .

Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status

J. Esteve, J. Bourhis, M. Labopin, 2016, Haematologica.

Diffuse pulmonary alveolar hemorrhage after allogeneic bone marow transplantation

D. Huhn, W. Siegert, I. Schmidt-Wolf, 1993, Annals of Hematology.

Soluble interleukin 2 receptors in patients after bone marrow transplantation.

D. Huhn, W. Siegert, G. Henze, 1990, Bone marrow transplantation.

Effects of physical exercise on survival after allogeneic stem cell transplantation

M. Bohus, P. Dreger, J. Wiskemann, 2015, International journal of cancer.

Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

W. Hiddemann, K. Spiekermann, C. Haferlach, 2012, Bone Marrow Transplantation.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study

W. Hiddemann, S. Bohlander, C. Buske, 2018, Leukemia.

Durable Remission after Prophylactic Donor Lymphocyte Transfusion Following Allogeneic Stem Cell Transplantation with Reduced Conditioning for High-Risk AML and MDS.

G. Ledderose, H. Kolb, C. Schmid, 2004 .

Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.

W. Siegert, N. Kröger, A. Zander, 2002, Annals of hematology.

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

S. Iacobelli, A. Nagler, K. Peggs, 2004 .

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.

W. Siegert, A. Kiani, G. Ehninger, 2009 .

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission

J. Esteve, J. Sierra, M. Labopin, 2020, British journal of haematology.

Comparison of plasmafractionation filters and filtration techniques in the clinical practice of LDL-apheresis.

I. Schwaner, R. Schwerdtfeger, H. Baeyer, 1986, ASAIO transactions.

transplantation: a retrospective collaborative analysis High-resolution HLA matching in hematopoietic stem cell

K. Schwarz, H. Einsele, M. Pfreundschuh, 2013 .

Extrakorporale Lipidelimination (LDL-Apherese) in der Behandlung der familiären Hypercholesterinämie: Differentialfiltration versus Dextransulfat-Adsorption - Extracorporeal Lipid Elimination (LDL-apheresis) in the Treatment of Familial Hypercholesterolemia: Differential Filtration versus Dextran Su

W. Schwartzkopff, H. Gräfenhahn, H. v. Baeyer, 1988 .

The Impact of Transfusion-Dependency on the Outcome of Patients with Myelodysplastic Syndromes (MDS) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation after Myeloablative Conditioning.

P. Valent, U. Germing, G. Kobbe, 2007 .

Successful treatment of a patient with postpartum factor VIII inhibitor with recombinant human interferon α 2a

D. Huhn, R. Schwerdtfeger, G. Hintz, 1991 .

Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies.

T. Lipp, E. Thiel, N. Kröger, 2009 .

Membrane low density lipoprotein apheresis in patients with familial hypercholesterolemia

I. Schwaner, R. Schwerdtfeger, F. Kochinke, 1986 .

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

H. Serve, P. Bader, O. Ottmann, 2011 .

Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT

J. Esteve, J. Bourhis, M. Labopin, 2014 .

L. Kanz, A. Nagler, D. Niederwieser, 2006 .

N. Schmitz, N. Kröger, A. Zander, 2002, Blood.

Diagnostic value of tests for Toxoplasma gondii-specific antibodies in patients undergoing bone marrow transplantation.

O. Liesenfeld, T. Held, R. Schwerdtfeger, 2003, Clinical Laboratory.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Yon-Dschun Ko, Andreas Faldum, Christian Buske, 2013 .

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005, Blood.

Efficacy of plasmapheresis, cascade-filtration and dextran-sulfate adsorption apheresis with calculation of the recovery rate of lipids and lipoproteins.

R. Schwerdtfeger, W. Schwartzkopff, H. Gräfenhahn, 1988, Beitrage zur Infusionstherapie = Contributions to infusion therapy.

N. Schmitz, C. Crawley, N. Russell, 2006 .